A recent study has established that activating mutations involving at least one of the four genes involving the NF-κB pathway (MYD88, CD79A/B, and CARD11) are present in 30–40% of 161 patients affected with DLBCL, independently from their COO phenotype [20]. Here, MYD88 is linked to diffuse large B-cell lymphoma.